Previously, we reported that the combination of CTX coupled with pharmacologic inhibition of TAMs by Pexidartinib (PLX-3397), a CSF-1R small molecule inhibitor, was highly effective against aggressive, claudin-low murine mammary tumors in several syngeneic Trp53 null TNBC genetically engineered mouse models (GEMMs) that present with high TAM infiltration. This evidence concerns the gene TP53 and breast cancer.